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Abstract
Purpose: Hodgkin Lymphoma (HL) is highly curable with well-established treatment regimens; however, the impact
on patient’s health-related quality of life (HRQL) from diagnosis through survivorship is unclear. This systematic
review aimed to describe the available literature on HRQL in HL, assess the quality of these studies, identify gaps in
the literature and recommend further areas of research.
Methods: Following PRISMA guidelines, we performed a systematic review to include studies assessing the HRQL
in HL patients. Articles identified through database searches were screened and data extracted. Quality was
evaluated using a 6-point scale, adapted from published HRQL systematic reviews.
Results: Sixty five articles published between 1986 and 2015 met inclusion criteria. These included 53 (82 %) cross-
sectional studies; 12 (18 %) longitudinal studies, including three embedded in randomized trials; and three additional
longitudinal studies that began assessment at diagnosis. Study sample sizes of HL patients varied considerably with
only five (42 %) longitudinal studies including more than 50 patients. Multidimensional HRQL was assessed in 45
studies, single HRQL domains in 22 studies, and symptoms, including fatigue, in 28 studies.
Conclusions: The majority of studies employed a cross-sectional design, enrolling HL survivors at least 10 years after
the completion of therapy. Emphasis on HRQL following therapy may inform initial treatment decisions and long-term
survivorship goals. We recommend that future research include prospective, longitudinal randomized designs across
both treatment and time.
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Background
Hodgkin Lymphoma (HL) has well established treatment
regimens that have yielded highly effective, long-term
cure rates [1, 2]. In 2015, there were an estimated 9050
new cases of the disease, which is a much lower
incidence than more commonly occurring cancers. The
number of persons living with HL in 2012, however, was
estimated to approach 190,000 [3]. Thus, from an onco-
logic perspective the successful treatment for HL over
the last 25 years has led to a high number of long-term
survivors.
The incidence of HL is bimodal by age with the first peak
within adolescence and young adulthood, ages 15–40, and
the second after age 55 [4]. For younger people with HL,
the aggressive cancer treatment often interrupts important
developmental milestones, such as graduation from high
school or college, establishing relationships, finding a first
apartment or getting a job. Despite the decades of curative
therapy for HL, comparatively little is known about how
HL affects health-related quality of life (HRQL)—through
diagnosis and treatment. Therefore, healthcare providers
lack the information that they need regarding how best to
intervene in a timely and effective manner to mediate HL’s
acute and late-term effects.
HRQL is a multidimensional construct, which reflects
the World Health Organization’s definition of health as
incorporating physical, mental, and social health [5]. The
history of HRQL assessment largely parallels the advances
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in HL therapy with most of the instrument development
and large-scale validation studies for adults commencing
in the 1980’s. The first randomized controlled trial (RCT)
containing an HRQL outcome was reported in 1986 by
Croog and Levine [6]. In contrast, instrument develop-
ment for children lagged considerably, but psychometric-
ally robust measures are now available for most patients
across the age continuum. Several validated instruments
address the multidimensional construct, while others
focus on individual dimensions or domains of HRQL,
such as physical or psychosocial functioning. Still others
measure individual symptoms, such as pain, nausea or
fatigue. The selection of a particular instrument or instru-
ments is informed by the particular study question.
Although treatment regimens are well-established,
the impact on HL patient’s HRQL from diagnosis
through long-term survivorship is still unclear. In this
study, we report on a systematic review that we con-
ducted on the HRQL literature to answer the follow-
ing research question: What is the HRQL impact of
HL and its treatment as reflected in the current
literature? Our goals were to: (1) describe the avail-
able literature on HRQL in HL, (2) assess the quality
of these studies and, (3) identify gaps in the available
literature and recommend further areas of research.
Methods
Literature search strategy
Our review was guided by the PRISMA statement [7]. We
searched Medline, CINAHL and PsychInfo using Medical
Subject Headings and keywords, such as Hodgkin disease,
quality of life, health- related quality of life, well-being,
functional status, health status and experiential health
status for articles published since inception to end of May
2016 that reported primary HRQL data specific to HL pa-
tients. A priori, we sought studies that assessed single or
multi-dimensional HRQL domains or discrete symptoms,
such as fatigue. Study design was not part of the inclu-
sion/exclusion criteria as our goal was to examine the en-
tirety of the HRQL in HL literature. Studies were
excluded if they (1) did not report primary HRQL separ-
ately for HL patients or (2) were not available in English.
Following this database search, a citation analysis was per-
formed on review articles to identify additional articles
(see Fig. 1). This was done to ensure that this review
afforded the most comprehensive representation of the
literature. Selected articles included HL patients across
the age (children and adults) and care continuum, from
initial diagnosis through long-term survivorship.
Review of the abstracts and full-text articles
The six-member team initially reviewed a training set of
50 abstracts for consideration in the study, applying estab-
lished inclusion/exclusion criteria to ensure consistency
across all team members. Subsequently, teams of two re-
viewers independently applied inclusion/exclusion criteria
to the remaining abstracts and then full text articles, re-
solving any discrepancies through consensus. Full text ar-
ticles meeting inclusion criteria were independently data
extracted using a standardized data extraction form and
checked for accuracy by a second review.
Review articles were handled differently from original
reports. Because the review articles did not include
original data, we did not perform data extraction on
review articles. The review articles provided background
information and were used in the citation analysis.
Quality indicators
The methodological quality of each study was evaluated
by a set of six predetermined criteria, adapted from
previously published systematic reviews [8, 9]. Quality
assessment (QA) criteria included: (1) description of ≥2
demographic variables specific to HL patients, such as
age and gender; (2) ≥2 clinical characteristics, specific to
HL patients, such as stage or site of disease; (3) sample
size ≥50 HL participants; (4) HL-specific HRQL scores;
presented as a mean summary score and measure of
variability in either table or text format; (5) analysis of
HRQL scores by HL specific demographic characteristics
and (6) HL results compared within groups. The final
QA checklist scores were summed by each article to give
an overall quality score, ranging from 0 to 6 in which
higher scores indicated higher quality.
Results
The database search totaled 792 unique records. Follow-
ing the screening process, 80 studies, published between
1986 and 2015, were identified, including 65 primary
studies and 15 review articles. Reasons for rejection of
full text articles included HL data not separated out, no
HRQL data reported, not available in English, or an
editorial article. The following section reports on the 65
primary studies.
Study characteristics
Study characteristics are presented in Table 1. Of the 65
studies, 53 (82 %) utilized cross-sectional design; only 12
(18 %) used longitudinal design. Of the 12 longitudinal
studies, seven included individuals who were off treat-
ment, while five included samples who were both on and
off treatment. We identified three longitudinal RCTs [10–
12], of which patients were followed from the time of
diagnosis through up to 10 years of survivorship. These
studies accrued large samples and made comparison of
HRQL according to randomized treatment groups. The
53 cross sectional studies reported on 35 unique cohorts
and only one included patients both on and off treatment.
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The remaining 52 (98 %) cross-sectional studies only in-
cluded individuals who were off active treatment.
The sample size of HL patients varied considerably
with 78 % of studies including a sample of 50 or more
HL patients. For the 53 cross-sectional studies, the
median sample size was 135 (range 15–1843) and for
the 12 longitudinal studies the median sample size was
51 (range 12–3208). The majority of study designs were
cohort (n = 45) and 14 used a comparator cohort design.
The most common comparators were the general popu-
lation (n = 23), other cancer patients (n = 12) and siblings
(n = 3). When comparing among other cancer patients,
the most common comparator included other types of
lymphoma (n = 7). The majority of studies relied on
remote data collection (n = 42), when specified either by
mail (n = 35) or telephone (n = 6), with the remainder
conducted in person. The study funding was primarily
investigator initiated (n = 58) or via a cooperative group
(n = 7). We did not identify any industry-funded studies.
Half (52 %) of the identified studies were published after
2005. Table 2 contains the data extraction results.
Patient characteristics
Age was reported in 54 studies (83 %). Thirty-three studies
reported a mean age of 40 years (SD = 8.5) and 21 studies
reported median age of 38 years (range 22–52). In 41
(63 %) studies that reported time since diagnosis, the mean
was 11.8 years (n = 25) and the median was 12.4 years (n =
16). Twelve (19 %) studies reported time post treatment,
with a mean of 4.8 years (SD = 1.73) (n = 4) and a median
of 10.2 years (n = 3). Five studies reported only a range of
years post treatment (1–23 years).
Quality of life measures
Studies varied by aspect of HRQL examined as well as
by specific instrument used. Table 3 summarizes the
various aspects of HRQL by study design (longitudinal
vs. cross-sectional). The most commonly used multi-
dimensional instruments were the EORTC QLQ-C30
(n = 18), the SF-12 or SF-36 (SF-36 Family) (n = 18) and
Health Utilities Index (HUI) 2, 3 (n = 8). Strikingly, all
12 longitudinal studies included a multidimensional
scale whereas only 62 % (n = 33) of the cross-sectional
Fig. 1 Systematic review flow diagram following PRISMA guidelines
Linendoll et al. Health and Quality of Life Outcomes  (2016) 14:114 Page 3 of 14
studies did so. Among cross-sectional studies, the most
commonly used measures were the HADS (n = 8), Fa-
tigue Questionnaire (n = 7), and the EORTC QLQ-C30
(n = 7).
Multi-dimensional HRQL scores varied by treatment
type [10, 13, 14], age and sex [11], comorbidities [15] or
late effects [16–18]. Both Khimani and Adams found
significantly lower quality of life among HD survivors
who experienced cardiopulmonary late effects [16, 18].
Goodman and Minn found that HD patients undergo-
ing autologous stem cell transplant reported no differ-
ence in global HRQL versus the general population,
however these patients did experience a decrease in
overall cognitive and social health [19, 20]. Finally,
Ganz found that HRQL can improve over the trajectory
of treatment into survivorship [10] and Mols supported
this finding that HRQL continues to improve through
long-term survivorship [21].
Among the single domains explored, psychosocial was
the most frequently identified with the psychosocial
assessments more common in cross-sectional (38 %) com-
pared to longitudinal (33 %) studies. The most frequently
used psychosocial instruments included the Hospital Anx-
iety and Depression Scale (HADS) (n = 13), the Brief
Symptom Inventory Scale (BSI) (n = 6), the Profile of
Mood States (POMS) (n = 5) and the Psychosocial Adjust-
ment to Illness Scale (PAIS) (n = 5). As studies utilized a
variety of scales and measures, the results within this do-
main were inconsistent and the presence of psychosocial
distress varied among reports. Early studies indicated that
HL survivors experienced increased psychological distress
[22–24], which was later supported by Oerlemans [25];
however, several others studies found no difference in the
psychosocial distress of HL survivors when compared to
healthy controls [26–28].
The second most commonly assessed domain was sexual
health (n = 7). When assessing sexual health, researchers
used four validated sexual health instruments including
the Sexual Health Scale, the Global Sexual Satisfaction
Index, the Brief Sexual Function Inventory, and the Sexual
Function Scale. Four of the studies indicated that HL
survivors report increased SX problems [14, 22, 29, 30].
These SX problems can improve over time [11], but may
be more long lasting in higher-stage patients [12].
Several of studies used symptom-specific question-
naires (n = 29). Of these symptom assessments, the 76 %
majority focused on fatigue (n = 22). Other symptom as-
sessments included nausea (n = 3), energy level (n = 1),
pain (n = 1) and symptom distress (n = 1). The three
most commonly used fatigue instruments included the Fa-
tigue Questionnaire (FQ) (n = 12), the MFI (n = 5), and the
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-Fatigue) (n = 3). Results in this domain were more
homogenous with multiple studies indicating that HL sur-
vivors are at increased risk for fatigue when compared to
healthy controls [10, 31–34]. Studies within this domain
found correlations between fatigue and depression ([15,
32] and fatigue and cardiopulmonary late effects [18, 35].
Table 1 Study characteristics (N = 65)
Study design, n (%)
Comparator: RCT 3 (5)
Comparator: cohort 14 (22)
Cohort 45 (69)
Comparator: case control 3 (5)
Study type, n (%)
Longitudinal 12 (18)
Cross-sectional 53 (82)
Study setting, n (%)




Before 1995 6 (9)
1995 to 2004 25 (38)
2005 to June 2015 34 (52)
Study sponsor, n (%)
Cooperative group 7 (11)
Investigator initiated 58 (89)





Other Europe 10 (15)




Median (range) 132 (12–3208)
25–75th percentile 58–280
Treatment status, n (%)
Active and off treatment 6 (9)
Off treatment only 59 (91)
Agea
Mean (n = 33) 39.6
Median (n = 21) 38
Gender, %
Female (n = 54) 44.0 %
Range 0–100 %
aAge: 3 studies with multiple arms, 6 studies NS
RCT randomized controlled trial, NS not stated
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Table 2 Studies assessing HRQL in Hodgkin lymphoma patients (N = 65)












Fobair P [26] 1986 Cohort Cross-
sectional
Median 9 years post
treatment





Kornblith AB [22] 1990 Cohort Cross-
sectional
6.3 years mean post
treatment
273 37 mean Off PAIS-SR, BSI, POMS, IES, Global
Sexual Satisfaction Index
Domain 5
Chao NJ [37] 1992 Cohort Longitudinal <1 year post treatment 24 N/S Off Study-specific
questionnaire
MultiD 2
Kornblith AB [23] 1992 Cohort Cross-
sectional
Mean 6.3 years post
treatment
273 37 mean Off PAIS-SR, BSI, POMS, Global
Sexual Satisfaction Index
Domain 6
Kornblith [48] AB 1992 Cohort Cross-
sectional
Mean 2.2 years post
treatment
93 35 median Off PAIS-SR, BSI, POMS, IES Domain 4




1 or more years post
treatment
85 32.3 mean Off POMS, CES-D, Social
Activity Scale
Domain 6




Mean 14 years since
diagnosis









Mean 10 years since
diagnosis





Norum J [50] 1996 Cohort Cross-
sectional
Median 48 months since
diagnosis
42 38 median Off IES, VAS Domain,
Other
4
Norum J [51] 1996 Cohort Cross-
sectional
Median 48 months since
diagnosis
42 38 median Off EuroQol MultiD 4
Norum J [52] 1996 Cohort Cross-
sectional
Median 48 months since
diagnosis
42 38 median Off EORTC QLQ-C30 MultiD 3
Abrahamsen AF [29] 1998 Cohort Cross-
sectional
Mean 12 years since
diagnosis
459 44 median Off Study-specific
questionnaire
Domain 6




Mean 5.9 years post
treatment
273 37 median Off PAIS-SR, BSI, POMS, IES Domain 6
Greil R [13] 1999 Cohort Cross-
sectional
Mean 10.5 years since
diagnosis
126 36.9 mean Off EORTC QLQ-C30 MultiD 6






459 44 mean Off SF-36, FQ MultiD,
Symptoms
5
Loge JH [54] 1999 Cohort Cross-
sectional
Mean 12.2 years since
diagnosis
459 44 mean Off HADS, FQ Domain,
Symptom
6
Loge JH [55] 1999 Cohort Cross-
sectional
Mean 12.2 years since
diagnosis
459 44 mean Off SF-36 MultiD 6
Van Schaik CS [56] 1999 Cohort Cross-
sectional
Median 21.9 years since
diagnosis
33 21.9 median Off HUI2, HUI3 MultiD 3
Loge JH [32] 2000 Cohort Cross-
sectional




























at least 2 years prior













92 37 mean Off FQ Symptom 6





135 N/S Both BSI Domain 3






1843 30.8 mean Off BSI Domain 5







Both SF-36, CARES-SF, SDS MultiD,
Symptom
4




46 43 mean Off EORTC QLQ-C30, HADS MultiD,
Other
5




53 41 fatigue, 40
non-fatigued
mean
Off SF-36, FQ MultiD,
Symptom
5















121 47 mean Off SEIQol-DW MultiD 5




48 31.9 median Off SF-36, Study-specific
questionnaire
MultiD 4




121 47 median Off SF-12, SEIQoL-DW, HADS MultiD,
Domain
6




496 46 median Off FQ Symptom 6






511 44 median Off FACIT-Fatigue Symptom 6




121 NS Off SF-12, SEIQoL-DW MultiD 2




479 46 mean Off SF-36, FQ MultiD,
Symptom
5




132 NS Off SF-36, QoL-CS MultiD 6




50 39.7 mean Off SF-12, HADS MultiD,
Domain
5





















Table 2 Studies assessing HRQL in Hodgkin lymphoma patients (N = 65) (Continued)
Mean since diagnosis:
14 years for males,








476 46 mean Off FQ Symptom 5




60 43 median Off EORTC QLQ-C30 MultiD 6




At least 15 years
since diagnosis
995 NS Off FACIT-Fatigue, Pittsburgh
Slee Quality Index, Epworth
Sleepiness Scale
Symptoms 4




15 NS Off HUI3 MultiD 2










Heutte N [11] 2009 Comparator:
RCT
Longitudinal Mean 7.5 years
since diagnosis












98 46 HDCT, 41
conventional
median
Off EORTC QLQ-C30, EQ-5D MultiD 6
Klaassen RJ [40] 2010 Cohort Longitudinal 2 weeks after
first course of
chemotherapy





Klaassen RJ [41] 2010 Comparator:
Cohort
Longitudinal 2 weeks after
first course of
chemotherapy









168 43.11 median Off EORTC QLQ-C30 MultiD 6




200 29 median Off MFI Symptom 4
Khimani N [18] 2013 Cohort Longitudinal Median 24 years
since diagnosis
273 52 median Off SF-36, FACIT-Fatigue MultiD,
Symptom
5




71 26 median Off EORTC QLQ-C30 MultiD 5
Behringer K [12] 2013 Comparator:
RCT







































Table 2 Studies assessing HRQL in Hodgkin lymphoma patients (N = 65) (Continued)




58 43.3 mean Off EORTC QLQ-C30, HADS MultiD,
Domain
6
Roper K [72] 2013 Cohort Longitudinal At completion of
planned therapy








200 29 median Off SF-12, QOL-CS, MOS-SSS, MFI MultiD,
Symptom
4




150 47 mean Off EORTC QLQ-C30 MultiD 6




725 28.44 mean Off EORTC QLQ-C30 MultiD 6










Daniels LA [73] 2014 Cohort Longitudinal Mean 21 years
since diagnosis






Oerlemans S [25] 2014 Comparator:
Case Control
Longitudinal Mean 4.7 years
since diagnosis
180 46.1 mean Off EORTC QLQ-C30, HADS MultiD,
Domain
6
Vermaete N [47] 2014 Comparator:
Cohort
Longitudinal Before the start
of chemotherapy
12 47 mean Both EORTC QLQ-C30, Distress Barometer MultiD,
Domain
5




131 46 median Off Fatigue questionnaire, HADS, SF36, Symptom,
MultiD
5






150 46.6 mean Off Fatigue assessment scale Symptom 4
Abbreviations: Tx treatment, MultiD multidimensional, HL Hodgkin’s Lymphoma, RCT randomized controlled trial, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire, SF-36/SF-12 Short Form, HUI Health Utilities Index, QOL-CS Quality of Life-Cancer Survivors, CES-D Center for Epidemiologic Studies Depression Scale, GSSI Global Sexual Satisfaction Index, IES Impact of
Event Scale, VAS Visual Analogue Scale, CARES-SF Cancer
Rehabilitation Evaluation System-Short Form, SDS Symptom Distress Scale, SEIQol-DW Schedule for the Evaluation of the Individual Quality of Life-Direct Weighting, PedsQL Pediatric Quality of Life Inventory, MOS-SSS
Medical Outcomes Study-Social Support Survey, FACT-BMT Functional Assessment of Cancer Therapy—Bone Marrow Transplant, FQ Fatigue Questionnaire, MFI Multi-Dimensional Fatigue Inventory, FACIT-Fatigue Func-
tional Assessment of Chronic Illness Therapy-Fatigue, HADS Hospital Anxiety and Depression Scale, BSI Brief Symptom Inventory, POMS Profile of Mood States, PAIS Psychosocial Adjustment to Illness Scale, HDCT high

















One longitudinal study with a small sample size showed
that an exercise intervention can improve fatigue in HL
survivors [36].
In our review, 63 (97 %) studies used at least one vali-
dated instrument. Two exceptions reported by Abrahamsen
[29] and Chao [37], used only non-validated, study-specific
questionnaires. Six other studies incorporated a study
specific questionnaire in addition to a validated instrument.
Of these, three included broad questions including demo-
graphic, medical and psychosocial information [26, 38, 39],
while the other three created assessment tools specific to
their study question pertaining to cardiac health [16],
patient screening [31], and psychiatric disorders [32].
Quality assessment
Our quality assessment was based upon six criteria
(Table 4). Nearly 86 % (n = 56) of all of the studies
included more than two demographic variables and clin-
ical characteristics. The majority (n = 53, 82 %) also
reported quality of life scores—specifically including a
mean score and standard deviation (SD) in table or text
form. Of the 11 studies that did not fulfill this criteria,
five presented the data graphically [10, 12, 40–42]; three
used the data to dichotomize groups (e.g., fatigued vs.
non-fatigued population) [36, 43, 44]; two provided
means scores but no standard deviation [41, 45]; one
provided the percentages of negative impact of sexual
function used to compare between groups [39], and one
reported the percentage of sexual problems [29]. Most
(n = 53, 82 %) of the studies compared results of individ-
uals with HL with other groups such as siblings, general
population or other individuals with cancer and 78 % of
the studies included a sample size greater than 50. For the
final criteria, 69 % of the studies included an analysis of
HL HRQL scores stratified by HL specific characteristics.
Key articles
The following section highlights specific studies with a
focus on their methodological rigor. The 2013 prospect-
ive study by Behringer et al. [12] was embedded within
German Hodgkin Study Group HD10-HD12 trials. This
study included the largest sample within our review,
3208 patients, and followed these patients from diagno-
sis through up to 27 months of follow-up care. Patients
were randomized to varying protocols of HL chemother-
apy and radiation, according to each of the three clinical
trials. This study ultimately focused on the sexual func-
tioning (SX) domain; however it also collected multi-
dimensional HRQL data. Studies instruments included
the European Organization for Research and the Treat-
ment of Cancer (EORTC-QLQ-C30), Multi-dimensional
Fatigue Inventory (MFI) and a Sexual Functioning Scale.
Researchers found that while SX was reduced at base-
line, it improved after therapy and eventually normalized
in individuals with early stage disease. Within the HD11
trial, which was a randomized comparison of doxorubicin,
bleomycin, vinblastine, and dacarbazine (ABVD) versus
bleomycin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine, procarbazine, and prednisone (BEACOPP), a small
but significant difference of SX symptoms was detected in
favor of ABVD. Long-term SX was related more to baseline
SX and patient characteristics than to the intensity of treat-
ment. Of note, older age, advanced stage disease, and fe-
male gender had an overall negative influence on SX.
From a quality perspective, the researchers used vali-
dated, multi-dimensional assessment tools; however they
did not report specific means scores or the standard
deviation. Instead, they used the HRQL data as inde-
pendent variables to predict/explain sexual function and
reported it in graph format. This absence of summary
scores and variance precludes performing meta-analysis
from these published data.
In 2003 Ganz et al. [10] conducted the only RCT of
HRQL in HL in the US. This study was embedded in a
RCT in cooperative Southwest Oncology Group 9133




n = 12 (18) n = 53 (82)
Multidimensional 12 (100) 33 (62)
Domain
Psychosocial 4 (33) 20 (38)
Sexual functioning 2 (17) 5 (9)
Physical 1 (8) 0 (0)
Symptom
Fatigue 4 (33) 18 (34)
Pain 0 (0) 1 (2)
Other 2 (4) 4 (8)
aPercentages do not sum to 100 because multiple measures can be used in
the same study, HRQL health-related quality of life








Sample >50 (HL Specific) 6 (42) 45 (85) 51 (78)
Description of >=2 Demos
(HL Specific)
10 (83) 48 (91) 58 (89)
Description of >=2 Clinical
Variables (HL Specific)
11 (92) 45 (85) 56 (86)
HL Specific HRQL Scores
(from validated measure)
8 (67) 45 (85) 53 (82)
Analysis of HL HRQL Scores ×
HL Characteristics
8 (67) 37 (70) 45 (69)
HL Results are compared
between groups?
9 (75) 44 (83) 53 (82)
HL Hodgkin’s Lymphoma, HRQL health-related quality of life
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trial. It included 247 patients in a prospective, longitu-
dinal design, evaluating multidimensional HRQL at
baseline, 6 months, 1 and 2 years. Researchers found a
statistical difference in HRQL between the two treat-
ments subtotal lymphoid irradiation with combined
modality treatment (CMT). Specifically, the CMT arm
experienced greater symptom distress, fatigue and
poorer overall HRQL; however, by years 1 to 2, patients
with in the two groups did not differ in outcomes. The
authors also reported that both groups experienced
significantly increased fatigue at 6 months from base-
line (when compared to healthy populations) and this
persisted even 1–2 years after treatment.
This study used a high quality methodology with a
prospective, longitudinal, RCT design, a large sample
size, and validated multi-dimensional assessment tools;
however, like Behringer [12], they did not report specific
means scores or the standard deviation, but instead pre-
sented trends over time graphically.
Heutte et al. [11] conducted a prospective, longitudinal
study assessing HRQL among patients treated on the H8
study in Europe. This study included 935 patients, who
were assessed at the end of therapy and serially up 10 years
following treatment using the EORTC-QLQ-C30, MFI, and
sexual function scale. Their results indicated that the emo-
tional functioning scores were more affected than the phys-
ical functioning scores, and that women reported lower
HRQL and increased symptom distress than men. All of
the HRQL domains they evaluated showed improvement
within 18 months of treatment completion with the excep-
tion of cognitive function and motivation. The authors sug-
gest that neither of these domains were affected by the HL
or treatment. Finally, they found that high levels of fatigue
at end of treatment predicted persistent fatigue into long-
terma follow-up. They did not find any differences between
the treatment groups. Methodologically, this study included
a large xsample size, randomization between treatment
groups and used validated, multi-dimensional assessment
tools. Methodologic concerns included the lack of baseline
data (prior to initiation of treatment) and no data obtained
during treatment.
Calaminus et al. [46] conducted a cross-sectional study
assessing HRQL in pediatric survivors, who were previously
treated for HL in German-Austrian RCT studies from 1978
to 2002. This study enrolled 725 participants, who were
assessed using the EORTC QLQ-C30. Results were com-
pared to a similarly matched general population sample.
Several of the results of this study are similar to Heutte’s:
survivors experienced worse emotional and social function-
ing compared to normal population; females experience
lower over-all functioning and higher symptom burden
than men; survivors experienced greater symptoms of
fatigue and sleep problems. Again, there was no relation-
ship between the treatment types. Methodologically, this
study included a large sample size, validated instruments
and comparisons between groups. Although it did not
follow patients over time, the study does illustrate how a
well-designed cross sectional study can support longitu-
dinal findings.
Klaassen et al. [40] examined the ability to detect change
over time in four different HRQL measures. In their pro-
spective study of 48 patients, patients were assessed at
four points in time: 2 weeks after first course of chemo-
therapy, during the second course of chemotherapy, dur-
ing their week of radiation and 1 year after diagnosis. All
of the HRQL measures demonstrated significant change
from Time 1 to Time 4. In a second study, Klaassen [41]
also examined proxy reporting by parents and nurses of
children with HL to determine if correlation with chil-
dren’s report. In this study, the authors found that over
the course of treatment there was statistical significant
agreement among the child, parent and nurse, as mea-
sured by the Spearman rank-order correlation coefficient.
Methodologically, this study used validated tools and
compared trends over time; however, concerns include its
small sample size, no baseline data, no randomization
according to the treatment arm or disease stage and the
absence of means scores with standard deviations.
Vermaete et al. [47] conducted a longitudinal study
to assess fatigue, physical activity and physical fitness in
individuals with lymphoma before, during and after
treatment. This study included 29 patients with either
HL (n = 12) or Non-Hodgkin Lymphoma (n = 17). Over
course of treatment, researchers detected a decline in
hemoglobin, physical force and oxygen uptake, and pa-
tients reported significantly increased fatigue. This study
looks deeper into the complex relationship between fatigue,
physical inactivity and deconditioning and support further
work in developing exercise interventions. Methodologic-
ally, this study used validated tools, obtained baseline prior
to the start of treatment and provided mean scores with
standard deviation; however, it enrolled a small sample size
and did not randomize according to the treatment arm or
disease stage.
Discussion
In our review the majority of studies employed cross-
sectional versus longitudinal design and of these cross-
sectional studies, 98 % enrolled participants off treatment.
These cross sectional studies capture patients within a
wide range of time periods after diagnosis, on average,
10 years after treatment. While cross sectional studies
provide a “snap shot in time,” analyzing a group one dec-
ade after treatment introduces the risk of many confound-
ing variables, which makes it difficult to build a cohesive
narrative around the impact of HL and its treatment on
HRQL. In terms of assessing HRQL, all longitudinal studies
used a multi-dimensional measure compared to 62 % of
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cross-sectional studies, which focused more on specific
domains and symptoms, especially fatigue.
The objective of this review was to systematically iden-
tify published studies reporting HRQL in individuals
with HL, and to examine the quality of these studies.
Our analysis points to several positive trends in the
literature. First, it is clear that that over time there has
been a growing interest in this topic, as the number of
studies that examine HRQL has increased. As noted, half
of the studies identified in this review were published
after 2005 (n = 34). The second positive trend is move-
ment toward more longitudinal studies with nine of the
12 published since 2009. In regard to patient reported
outcomes in HRQL, the majority of studies used at least
one multidimensional instrument (n = 45) and 97 % of
studies included at least one validated instrument.
We also noted several concerns with quality of the
current literature. The most rigorous methodology em-
ploys a longitudinal design with comparison between
groups and changes within subjects. Our review identi-
fied only 12 longitudinal studies with ten unique data
sets. Only five out of the 12 studies followed patients
from diagnosis through to post-treatment and of these
only two included at least 50 patients. Reporting HRQL
data also varied across the longitudinal studies with four
reporting results graphically without mean summary
scores and measures of variability [10, 12, 40, 41], which
prevents further meta-analysis.
Behringer and colleagues [12] illustrate the complex
and informative data that can be derived from prospect-
ive, longitudinal designs. It provides clinician’s with a
deeper understanding of the trajectory of SX from diag-
nosis through treatment; additionally, it describes how
SX differs across treatment groups and identifies those
specific populations, who are most vulnerable. This
information can assist clinicians in providing anticipa-
tory guidance and targeted-interventions to the most
vulnerable populations.
Results from Ganz and colleagues [10] inform clini-
cians that symptom burden can vary between treatment
groups; however fatigue can persist over time. Clinicians
could use this information to guide CMT patients to be
more realistic with short-term goals immediately after
treatment and to initiate more aggressive symptom
management interventions. Second, in regard to fatigue,
clinicians could use this information to prepare their
patients for fatigue, continue to assess for fatigue during
follow-up care and to support further research and inter-
ventions in fatigue prevention and management.
Relevance to research and clinical practice
This systematic review reveals the paucity of information
on the HRQL impact of initial diagnosis and treatment
on HL patients. The majority of published studies are
cross-sectional in design and relatively small in size; only
36 studies have sample sizes >100 (Table 2). This limits
the application of study findings due to concerns about
generalizability and reproducibility. That said, the few
longitudinal studies commencing prior to the initiation
of treatment, detailed on page 11, provide such informa-
tion about HRQL trajectory and how it changes over
time and by treatment. These findings offer compelling
evidence for the need to replicate these measures in
future trials.
This study has several strengths. First, we followed
PRISMA guidelines to systematically search the literature
to capture the complete and relevant published literature.
Second, the quality assessment methods provided a stan-
dardized measure by which all articles were evaluated.
Last, we highlighted the subset of articles which exemplify
best practices to examine HRQL in HL patients, with the
goal of building upon these methods and findings in fu-
ture research.
Limitations
There are limitations to this study. First, because of the
lack of RCTs on this topic, we included observational
studies, which are more open to bias. Second, we did
not conduct an assessment of publication bias as our
aim was to analyze the quality rather than to meta-
analyze the findings. Last, most HRQL assessments were
completed post-treatment so the longitudinal trajectory
of HRQL was not captured. More large-cohort, pro-
spective studies are needed to address this limitation.
Conclusions
HL is a highly curable disease with standardized treatment
paradigms over the last two decades. Although the treat-
ment is well established, a knowledge gap still exists in un-
derstanding how this diagnosis and its treatment affect
the individual’s HRQL from diagnosis though long-term
survivorship. Further, with the exception of an ongoing
pediatric cooperative group trial, we found no prospective
pediatric studies reporting on HRQL in HL from diagnosis
to survivorship. Even in adult studies, we identified a sub-
stantial void of HRQL data during the active treatment
phase. Finally, we identified no industry-funded studies,
although this may change with the emergence of novel
therapeutics.
With the growing interest and acknowledgement of
the importance of HRQL, we recommend that future re-
search studies employ greater methodological rigor by
including prospective, longitudinal randomized designs
across both treatment and time. Behringer [12], Heutte
et al. [11] and Ganz [10], provide a “gold standard” of re-
search studies that not only examine longitudinal effects
within subject changes, but also provide comparisons
between different treatment regimens. The information
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generated by these longitudinal studies helps clinicians
target vulnerable populations and provide anticipatory
guidance to patients. Such studies will generate further
data that clinicians can use to address “real life” HRQL
problems that patients face on a day-to-day basis. Fur-
ther, while research supports that HRQL improves after
treatment, continued deficits in some patients within the
domains of fatigue, sexual and psychosocial health war-
rants further study with targeted interventions to miti-
gate the risk of poorer HRQL. Finally, as the focus on
HRQL continues to grow in importance, researchers
should consider partnering with industry to examine on-
cologic treatments within the context of how they will
impact the patient’s HRQL.
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